Abbott Diabetes Care Inc. is celebrating a Delaware federal court’s decision that DexCom, Inc. continuous glucose monitor (CGM) infringed on one of its patents. The damages, however, are still to be determined.
Originally, Abbott sought damages of $1.3bn from profits lost to sales of DexCom’s CGM, the G6 line of products
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?